Cargando…

Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells

BACKGROUND: RRM1 is functionally associated with DNA replication and DNA damage repair. However, the biological activity of RRM1 in pancreatic cancer remains undetermined. METHODS: To determine relationships between RRM1 expression and the prognosis of pancreatic cancer, and to explore RRM1 function...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Tomotaka, Ono, Hiroaki, Fujii, Mikiya, Akahoshi, Keiichi, Ogura, Toshiro, Ogawa, Kosuke, Ban, Daisuke, Kudo, Atsushi, Tanaka, Shinji, Tanabe, Minoru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191885/ https://www.ncbi.nlm.nih.gov/pubmed/34111175 http://dx.doi.org/10.1371/journal.pone.0252917

Ejemplares similares

RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer
por: Ono, Hiroaki, et al.
Publicado: (2023)

C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer
por: Ono, Hiroaki, et al.
Publicado: (2021)

Current topics in the surgical treatments for hepatocellular carcinoma
por: Ban, Daisuke, et al.
Publicado: (2018)

Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers
por: Murase, Yoshiki, et al.
Publicado: (2021)

Successful conversion surgery of distal pancreatectomy with celiac axis resection (DP-CAR) with double arterial reconstruction using saphenous vein grafting for locally advanced pancreatic cancer: a case report
por: Murase, Yoshiki, et al.
Publicado: (2020)

Pancreatic metastasis from renal cell carcinoma presenting as gastrointestinal hemorrhage: a case report
por: Matsui, Satoshi, et al.
Publicado: (2021)

Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection
por: Sugawara, Toshitaka, et al.
Publicado: (2021)

Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms
por: Murase, Yoshiki, et al.
Publicado: (2021)

Laparoscopic distal pancreatectomy in a patient with aberrant splenic artery originating from the superior mesenteric artery: A case report
por: Ishida, Hiroyuki, et al.
Publicado: (2021)

Identification of a novel target of SETD1A histone methyltransferase and the clinical significance in pancreatic cancer
por: Ishii, Takeshi, et al.
Publicado: (2022)

Comprehensive molecular and immunological characterization of hepatocellular carcinoma
por: Shimada, Shu, et al.
Publicado: (2018)

MGMT is frequently inactivated in pancreatic NET-G2 and is associated with the therapeutic activity of STZ-based regimens
por: Yagi, Kohei, et al.
Publicado: (2023)

DEPDC5 deficiency contributes to resistance to leucine starvation via p62 accumulation in hepatocellular carcinoma
por: Mizuno, Yuki, et al.
Publicado: (2018)

Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
por: Jørgensen, Charlotte LT, et al.
Publicado: (2013)

Dynamic Enhancement Pattern on CT for Predicting Pancreatic Neuroendocrine Neoplasms with Low PAX6 Expression: A Retrospective Observational Study
por: Kimura, Koichiro, et al.
Publicado: (2020)

Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma
por: Akasu, Masafumi, et al.
Publicado: (2021)

Loss of SFXN1 mitigates lipotoxicity and predicts poor outcome in non-viral hepatocellular carcinoma
por: Yagi, Kohei, et al.
Publicado: (2023)

Extraordinary first jejunal arterial variation associated with annular pancreas undergoing pancreaticoduodenectomy for pancreatic cancer: a case report
por: Iwao, Yasuhito, et al.
Publicado: (2021)

Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma
por: Zhao, Li-Ping, et al.
Publicado: (2012)

Loss of KDM6B epigenetically confers resistance to lipotoxicity in nonalcoholic fatty liver disease–related HCC
por: Hatano, Megumi, et al.
Publicado: (2023)

RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine
por: Chen, Ying, et al.
Publicado: (2018)

Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients
por: Boukovinas, Ioannis, et al.
Publicado: (2008)

The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
por: Mlak, R., et al.
Publicado: (2015)

RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
por: Chun, Jung Won, et al.
Publicado: (2021)

MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy
por: Lu, Huimin, et al.
Publicado: (2019)

A Kinome Screen Identifies Checkpoint Kinase 1 (CHK1) as a Sensitizer for RRM1-Dependent Gemcitabine Efficacy
por: Zhou, Jun, et al.
Publicado: (2013)

Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
por: Xia, Guanggai, et al.
Publicado: (2017)

RRM1 *151A>T, RRM1 ‐756T>C, and RRM1 ‐585T>Gis associated with increased susceptibility of lung cancer in Chinese patients
por: Xu, Xiao‐Ling, et al.
Publicado: (2016)

ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine
por: Ulker, Mehmet, et al.
Publicado: (2015)

RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy
por: Dong, Song, et al.
Publicado: (2010)

RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy
por: Yang, Zhenxing, et al.
Publicado: (2019)

Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells
por: Zhang, Xia, et al.
Publicado: (2021)

Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma
por: Nakao, Keisuke, et al.
Publicado: (2015)

Exome sequencing identifies a novel missense variant in RRM2B associated with autosomal recessive progressive external ophthalmoplegia
por: Takata, Atsushi, et al.
Publicado: (2011)

Structural study of the Fox-1 RRM protein hydration reveals a role for key water molecules in RRM-RNA recognition
por: Krepl, Miroslav, et al.
Publicado: (2017)

RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin
por: Muñoz-Montaño, Wendy, et al.
Publicado: (2021)

A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models
por: Matsumoto, Takeshi, et al.
Publicado: (2021)

The Clinical and Prognostic Significance of Ribonucleotide Reductase Subunits RRM1 and RRM2 mRNA Levels in Patients with Chronic Lymphocytic Leukemia
por: Chatzidavid, Sevastianos, et al.
Publicado: (2023)

P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer
por: Ono, Hiroaki, et al.
Publicado: (2016)

Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis
por: Ito, Hiromitsu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nt59t075dsfh7d7b4jbbnn1sfc